Elevance Health (ELV) Faces CMS MA Sanctions and Boosts Social Impact Efforts Is Its Model Evolving?

• In late February and early March 2026, Elevance Health disclosed that CMS plans to sanction its Medicare Advantage-Prescription Drug plans over alleged risk adjustment data issues, while also announcing leadership changes at Carelon and supporting a national diaper access pilot with the National Diaper Bank Network.
• The combination of potential CMS enrollment sanctions in a key Medicare Advantage segment and Elevance’s expanded community health initiatives raises important questions about regulatory risk, operational resilience, and the role of social impact programs in its long-term health benefits model.
• We’ll now examine how the potential CMS enrollment sanctions on Medicare Advantage plans may affect Elevance Health’s previously outlined investment narrative.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Elevance Health Investment Narrative Recap

To own Elevance Health, you need to believe its integrated health benefits and services model can still compound earnings despite pressure in government programs. Right now, the key near term catalyst is management’s ability to keep margins on track in Medicare and Medicaid. The potential CMS enrollment sanctions in Medicare Advantage are a material new overhang, since they directly touch a core growth area and add incremental regulatory and reputational risk.

The most relevant recent development here is CMS’s planned sanctions on Elevance’s Medicare Advantage Prescription Drug plans tied to historical risk adjustment data submissions, backed by an investor investigation into potential securities issues. This sits squarely against earlier expectations that government programs would be a steady growth pillar and highlights how regulatory oversight can quickly alter the risk reward balance around Elevance’s Medicare strategy and its margin recovery thesis.

Yet behind Elevance’s investments in AI, value based care, and Carelon’s expansion, investors should also be aware that…

Read the full narrative on Elevance Health (it’s free!)

Elevance Health’s narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and about a $2.0 billion earnings increase from $5.4 billion today.

Uncover how Elevance Health’s forecasts yield a $387.85 fair value, a 34% upside to its current price.

Exploring Other PerspectivesELV 1-Year Stock Price Chart

Before this CMS news, the most optimistic analysts were assuming Elevance could reach about US$234.6 billion in revenue and US$8.4 billion in earnings by 2028, but if you worry about growing regulatory scrutiny on government programs, you can see how quickly those upbeat expectations might be tested and why it is worth comparing these views with more cautious scenarios.

Explore 10 other fair value estimates on Elevance Health – why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Elevance Health research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Elevance Health’s overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com